Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03603964




Registration number
NCT03603964
Ethics application status
Date submitted
19/07/2018
Date registered
27/07/2018
Date last updated
26/04/2023

Titles & IDs
Public title
Guadecitabine Extension Study
Scientific title
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
Secondary ID [1] 0 0
SGI-110-12
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia 0 0
Myeloid Dysplastic Syndrome 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Guadecitabine

Experimental: Guadecitabine - Participants received guadecitabine, subcutaneous (SC) injection on Days 1-5 of each 28-day cycle at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol.


Treatment: Drugs: Guadecitabine
Guadecitabine
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
From the start of study treatment until 30 days after the last dose of study treatment or prior to the participant receiving alternative anticancer therapy, whichever occurs first.
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
From randomization in the prior study to the date of death

Eligibility
Key inclusion criteria
1. Previous participation in an Astex-sponsored guadecitabine clinical trial [including
but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT03603964), SGI-110-05,
SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)], in which the participant was
treated with guadecitabine and was still on active treatment with guadecitabine at the
time of database close for the prior study.

2. Participant is considered to be benefitting from guadecitabine treatment in the
opinion of the treating investigator.

3. Able to understand and comply with the study procedures, understand the risks involved
in the study, and provide written informed consent before any study-specific
procedure.

4. Women of child-bearing potential (according to recommendations of the Clinical Trial
Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a
negative pregnancy test at screening. Women of child-bearing potential and men with
female partners of child-bearing potential must agree to practice 2 highly effective
contraceptive measures while receiving treatment with guadecitabine and for at least 3
months after completing treatment and must agree not to become pregnant or father a
child while receiving study treatment and for at least 3 months after completing
guadecitabine treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- 1. Any participant who, in the opinion of the investigator, may have other conditions,
organ dysfunction, or have safety data from their prior study participation that
suggest that the risks of continuing treatment with guadecitabine may outweigh the
benefits.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/07/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/10/2021
Sample size
Target
Accrual to date
Final
35
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
United States of America
State/province [2] 0 0
North Carolina
Country [3] 0 0
United States of America
State/province [3] 0 0
Ohio
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Tennessee
Country [6] 0 0
Austria
State/province [6] 0 0
Styria
Country [7] 0 0
Canada
State/province [7] 0 0
Ontario
Country [8] 0 0
Denmark
State/province [8] 0 0
Copenhagen
Country [9] 0 0
Italy
State/province [9] 0 0
Alessandria
Country [10] 0 0
Italy
State/province [10] 0 0
Genova
Country [11] 0 0
Italy
State/province [11] 0 0
Milano
Country [12] 0 0
Italy
State/province [12] 0 0
Udine
Country [13] 0 0
Japan
State/province [13] 0 0
Isehara-shi
Country [14] 0 0
Japan
State/province [14] 0 0
Kyoto-shi
Country [15] 0 0
Japan
State/province [15] 0 0
Saga-shi
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Korea, Republic of
State/province [17] 0 0
Ulsan
Country [18] 0 0
Spain
State/province [18] 0 0
Madrid
Country [19] 0 0
Taiwan
State/province [19] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astex Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter, open-label extension study for participants who participated in a
previous Astex-sponsored guadecitabine clinical study [including but not limited to
SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07
(NCT02907359)].
Trial website
https://clinicaltrials.gov/ct2/show/NCT03603964
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03603964